As of today (2024-04-23), Evotec SE's share price is $7.625.
Evotec SE's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.25. Hence, Evotec SE's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Evotec SE's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Evotec SE's highest Price-to-Free-Cash-Flow Ratio was 4695.00. The lowest was 15.74. And the median was 58.52.
EVO's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 21.05 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Evotec SE was -183.70% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.30% per year.
During the past 13 years, Evotec SE's highest 3-Year average Free Cash Flow per Share Growth Rate was 230.20% per year. The lowest was -95.80% per year. And the median was 12.00% per year.
Evotec SE Price-to-Free-Cash-Flow Historical Data
The historical data trend for Evotec SE's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Price-to-Free-Cash-Flow Distribution
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Evotec SE's Price-to-Free-Cash-Flow falls into.
Evotec SE Price-to-Free-Cash-Flow Calculation
Evotec SE's Price-to-Free-Cash-Flow ratio for today is calculated as
Evotec SE's Share Price of today is $7.625.
Evotec SE's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Evotec SE (NAS:EVO) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Evotec SE Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Evotec SE's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EVO has been successfully added to your 